Key result
Plasma TMSB4 levels were significantly elevated in patients with first-onset AMI compared to controls (1093 vs 421 ng/mL; P<0.001), showing strong diagnostic potential with an AUC of 0.849.
Why the study?
Plasma protein alterations occur in acute myocardial infarction, prompting investigation of plasma proteomics in first-onset AMI to identify novel diagnostic targets.
Does plasma TMSB4 level accurately diagnose first-onset myocardial infarction compared to healthy controls?
Case-Control (n=400)
Does plasma TMSB4 level accurately diagnose first-onset myocardial infarction compared to healthy controls?
Answers are grounded in this paper and cite their sources.
Plasma TMSB4 levels are significantly elevated in first-onset AMI and correlate strongly with cardiac troponin I, suggesting its potential as a novel diagnostic biomarker.
Background Plasma protein alterations may occur in patients with acute myocardial infarction (AMI). In this study, we investigated the plasma proteomics of patients with first‐onset AMI to identify a novel diagnostic target for myocardial infarction. Methods Using a case–control design, we recruited 6 patients with first‐onset AMI and 6 age‐ and sex‐matched healthy controls. Mass spectrometry was used to analyze their plasma proteomics. Additionally, we enrolled 156 patients with AMI and 232 healthy individuals to validate the differentially expressed proteins using ELISA. Results A total of 58 differentially expressed proteins were identified between the 2 groups ( P <0.05, fold change ≥2 or ≤1/2), including 36 upregulated and 22 downregulated proteins. Notably, we discovered a clinically significant protein, thymosin β4 (TMSB4), which was subsequently validated by ELISA. Plasma TMSB4 levels were significantly elevated in patients with first‐onset AMI compared with the control group (1093 [701–1608] ng/mL versus 421 [245–658] ng/mL; P <0.001). Univariate and multivariate logistic regression analyses indicated that TMSB4 is a risk factor for first‐onset AMI. The receiver operating characteristic curve yielded an area under the curve value of 0.849, with an optimal cutoff of 682 ng/mL, sensitivity of 0.808, and specificity of 0.793. A robust correlation was observed between TMSB4 and cardiac troponin I ( r =0.9044, P <0.0001), and the κ test yielded a moderate concordance value (κ=0.590 [95% CI, 0.509–0.671]; P <0.001). Conclusions TMSB4 holds diagnostic value for first‐onset myocardial infarction and may therefore be considered a potential diagnostic marker for infarction. Registration URL: https://www.chictr.org.cn/ ; unique identifier: ChiCTR2300078144.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) conducted a case-control in First-onset acute myocardial infarction (n=400). Elevated plasma Thymosin β4 (TMSB4) levels vs. Healthy controls was evaluated on Plasma TMSB4 levels (ng/mL) (AUC 0.849, p=<0.001). Plasma TMSB4 levels were significantly elevated in patients with first-onset AMI compared to controls (1093 vs 421 ng/mL; P<0.001), showing strong diagnostic potential with an AUC of 0.849.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: